NCT01863485CompletedPhase 1
Phase 1 Safety, Tolerability, and Pharmacokinetic Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China
AnewPharma3 sites in 1 country44 target enrollmentStarted: May 2013Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 44
- Locations
- 3
- Primary Endpoint
- Maximum Tolerated Dose
Study Overview
Brief Summary
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With Advanced Solid Tumors.
Detailed Description
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With Advanced Solid Tumors. After the maximum tolerated dose (MTD) or the optimal biological dose is identified, an expansion cohort of ~20 advanced renal cell carcinoma patients will be enrolled to further characterize the safety and tumor response by CT.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy that is not responsive to standard therapies or for which there is no effective therapy.
- •Eastern Cooperative Group (ECOG) Performance Status score of 0 or
- •Life expectancy of at least 12 weeks.
- •No immuno deficiency.
- •Adequate organ system function, defined as follows:
- •Absolute neutrophil count (ANC) ≥1.5 x 10**9/L
- •Platelets ≥100 x 10**9/L
- •Hemoglobin ≥10 g/dL
- •Total bilirubin ≤1.5 times the upper limit of normal (ULN)
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5x the upper limit of normal (ULN) if no liver involvement or ≤2.5x the upper limit of normal with liver involvement.
- •Creatinine ≤ 1.5 x ULN.
- •At least 4 weeks or 5 half-life after receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization.
- •Willingness and ability to comply with trial and follow-up procedures.
- •Ability to understand the nature of this trial and give written informed consent.
Exclusion Criteria
- •Not recovered from prior anti-cancer therapy or surgery.
- •Have taken strong cytochrome P450 3A4 inhibitors or inducers in the last 2 weeks.
- •Concomitant use of drugs with a risk of causing prolonged corrected QT interval and/or Torsades de Pointes.
- •Patients with a history of intolerance to, or significant toxicity with, VEGFR tyrosine kinase inhibitor(s) (TKI).
- •Females who are pregnant or breastfeeding.
- •Those in reproductive ages who refuse to use contraception.
- •Those with concurrent condition(e.g. psychological, neuronal, cardiovascular, respiratory conditions or infections) that in the investigator's opinion would jeopardize compliance with the protocol.
- •Patients with known central nervous system (CNS) metastases.
- •Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of CM082 (X-82).
- •Patients with known GI disorders such as vomiting, diarrhea.
- •Patients who are hepatitis B virus positive.
- •Drug abuser.
Arms & Interventions
CM082
Experimental
CM082 tablet
Intervention: CM082 Tablet (Drug)
Outcomes
Primary Outcomes
Maximum Tolerated Dose
Time Frame: 12 months
To determine the Maximum Tolerated Dose in Chinese patients with advanced solid tumors.
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (3)
Loading locations...
Similar Trials
Completed
Phase 1
First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT04577703Sunshine Lake Pharma Co., Ltd.20
Terminated
Phase 1
A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).Cutaneous T-cell Lymphoma (CTCL)NCT05156229Codiak BioSciences2
Completed
Phase 1
APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis BChronic Hepatitis BNCT03585322Ascentage Pharma Group Inc.49
Terminated
Phase 1
A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)Fungal InfectionsNCT01716234Merck Sharp & Dohme LLC142
Completed
Phase 1
A Study Of CP-690,550 In Stable Kidney Transplant PatientsKidney TransplantNCT01710033Pfizer28